key: cord-0943546-k18xzd1q
authors: Ovsyannikova, Inna G.; Haralambieva, Iana H.; Crooke, Stephen N.; Poland, Gregory A.; Kennedy, Richard B.
title: The role of host genetics in the immune response to SARS‐CoV‐2 and COVID‐19 susceptibility and severity
date: 2020-07-13
journal: Immunol Rev
DOI: 10.1111/imr.12897
sha: 3ecd219d417b137a7905090f055302040705b103
doc_id: 943546
cord_uid: k18xzd1q

This article provides a review of studies evaluating the role of host (and viral) genetics (including variation in HLA genes) in the immune response to coronaviruses, as well as the clinical outcome of coronavirus‐mediated disease. The initial sections focus on seasonal coronaviruses, SARS‐CoV, and MERS‐CoV. We then examine the state of the knowledge regarding genetic polymorphisms and SARS‐CoV‐2 and COVID‐19. The article concludes by discussing research areas with current knowledge gaps and proposes several avenues for future scientific exploration in order to develop new insights into the immunology of SARS‐CoV‐2.

The 2019 outbreak of SARS-CoV-2, which began in Wuhan, China, refocused the world's attention on coronaviruses. Several seasonal coronaviruses are known to circulate in the human population and generally cause relatively mild respiratory tract infections, including the alphacoronaviruses HCoV-NL63 and HCoV-229E, and the betacoronaviruses HCoV-OC43 and HCoV-HKU1. Two of these viruses (OC43 and 229E) were first discovered in the late 1960s, while the other two (NL63 and HKU1) were identified in 2004 and 2005, respectively. 1 Phylogenetic evidence suggests that each of these four viruses originated from bat-(NL63 and 229E) or rodent-associated (OC43 and HKU1) coronaviruses. 1 These four seasonal coronaviruses account for 15%-30% of common colds in children and a smaller percentage of colds in adults. While seasonal coronavirus infections are generally mild, they can cause more severe disease in neonates and immunocompromised subjects. 2 4 SARS is believed to have arisen in bats, transferred to animals such as civet cats, and was then acquired by humans. 5 No further known cases have occurred since 2004.

MERS-CoV is a zoonotic betacoronavirus transmitted to humans from dromedary camels, with some evidence that it originated in bats. 6 MERS causes a wide range of infections in humans (from asymptomatic to severe pneumonia with high mortality rate of 34%). It originated in Saudi Arabia in 2012 and has led to 2494 confirmed cases and 858 associated deaths. 7 Unlike SARS, which disappeared after 2004, this virus continues to be a problem, with sporadic small numbers of cases continuing to occur primarily within the Arabian Peninsula.

In 2019, the seventh coronavirus known to infect humans was identified as the cause of the pandemic originating in Wuhan, China.

This virus, SARS-CoV-2, was initially associated with a respiratory disease termed COVID-19. Subsequently, a wide range of clinical outcomes have been observed among individuals diagnosed with COVID-19, ranging from mild respiratory infection to acute respiratory disease and death. [8] [9] [10] Disease severity is disproportionately higher among older adults and individuals with underlying comorbidities, 11 although severe cases of COVID-19 have also been reported among young and healthy individuals. 12 Symptomatology also varies widely, with case reports indicating gastrointestinal (GI) distress, sensorineural impairment, loss of smell and taste, dysregulated blood clotting, hepatitis, and acute cardiac and renal injury irrespective of age and health status. [13] [14] [15] [16] [17] [18] [19] The mechanisms underlying the variation in COVID-19 susceptibility and disease presenta- The HLA region of the human genome has been recognized for its importance in both disease risk and resistance. 21 HLA gene polymorphisms have been linked to numerous infectious diseases, including those caused by RNA viruses, such as SARS, influenza, HIV, hepatitis C, rabies, West Nile fever, rubella, mumps, measles, and F I G U R E 1 The impact of host genetics and viral variation on SARS-CoV-2 infection and COVID-19 severity. Individuals in the population harbor single nucleotide polymorphisms (SNPs) across a variety of genes (eg, ACE2, TMPRSS2, HLA, CD147, MIF, IFNG, IL6) that have been implicated in the pathology and immunology of SARS-CoV-2 and other pathogenic coronaviruses. These and other genetic variants may modulate disease susceptibility, increase or decrease disease severity, alter the variety of symptoms developed, and affect the magnitude and/or quality of the immune responses against SARS-CoV-2. In addition to host genetic variation, genetic variants of SARS-CoV-2 (and other pathogenic coronaviruses) can exhibit differences in biological activity. Single amino acid mutations in the spike glycoprotein can modulate ACE2 binding or alter B cell epitopes to promote immune escape or render monoclonal antibodies ineffective, while mutations in non-structural/accessory proteins can promote the development of resistance to antivirals, alter T cell epitopes, disrupt cell mediated immunity, and modulate host cellular interactions with viral particles others. Such genetic association studies and the insights they provide are critical to identifying the HLA alleles that may be associated with protective immune responses. Differential immune responses have been observed in mild and severe cases of COVID-19, including delayed IgM responses 22 and higher S protein IgG titers in non-ICU patients, 23 raising the questions of if and how HLA allelic variation contributes in this differential immunity. It is critical to determine and compare HLA profiles among individuals with serious cases of COVID-19 with those who have mild or no apparent disease. This will aid in understanding the underlying mechanisms of protective innate and adaptive immunity and may lead to the development of genetic markers as correlates of protection.

Herein, we review the current status of research focused on identifying genetic variants associated with the immune response 24 Genetic mapping in this study revealed several loci of interest, including a locus on chromosome 3 (with 23 genes and 13 non-coding RNAs) that contained the ubiquitin E3 ligase TRIM55 gene (tripartite motif containing 55), a RING zinc finger-containing protein with possible engagement in proteinprotein interactions, and a plausible role in SARS-CoV-induced vascular cufflink/inflammatory response in the lungs. 24 The implications of these findings for human coronavirus disease are unclear, and the impact of this locus/gene on coronavirus infection in humans has yet to be determined.

While much is known about the epidemiology, surveillance, transmission, shedding, and clinical manifestations of infections caused by the community-acquired viruses HCoV-NL63, HCoV-229E, HCoV-OC43, and HCoV-HKU1, limited data exist in the literature to elucidate the possible human genetic variation that may impact common cold coronavirus susceptibility and disease. 2, [25] [26] [27] One common target for studies evaluating host genetic factors is the viral receptors. Early animal studies in a murine model of mouse hepatitis coronavirus (MHV) provided proof-of-concept evidence for the critical role of the coronavirus entry receptor genotype/alleles (ie, CEACAM1) for susceptibility to coronavirus infection. 28, 29 Aminopeptidase N (CD13) is a cell surface metalloprotease that has been previously recognized as a receptor for HCoV-229E, 30 while ACE2 has been identified as a receptor for HCoV-NL63 31,32 ; however, genetic variation in these receptors has not been studied in relation to these infections. It has been demonstrated that cyclophilin A directly interacts with the nucleocapsid of SARS-CoV-1 34 and is incorporated into the purified virions. 35 Functional single nucleotide polymorphisms in cyclophilin A may directly affect the propagation of HCoV-229E. 33 Data on the host factors associated with the seasonal coronavirus infections may provide valuable insights into the genetic factors associated with SARS and COVID-19 susceptibility and progression.

Previous findings with SARS-CoV-1 have offered important-although often conflicting-insights regarding the plausible genetic influence of host factors on the susceptibility, pathogenicity, and clinical outcome of SARS. Most of these studies, which encompassed cohorts with limited sample size, relied on candidate gene approaches to investigate the genetic contribution of factors with a known or suspected role in coronavirus infection and pathogenesis. Because the angiotensin-converting enzyme 2 (ACE2 mapping on the human chromosome Xp22, and a homologue of ACE1 with 40% amino acid identity) has been established as an entry receptor for at least three coronaviruses (ie, SARS-CoV-1, HCoV-NL63, and SARS-CoV-2 [36] [37] [38] [39] [40] [41] , several studies have explored the impact of ACE2 polymorphisms on SARS susceptibility and disease severity. 42 16 antibody-positive contacts, and 137 other controls were investigated for the genetic association between 19 SNPs in or flanking the ACE2 gene and found no evidence for genetic association. 43 A recent GWAS study used a cohort of limited sample size (HCV-infected liver tissue samples from 195 subjects) to investigate associations between host genetic polymorphisms and ACE2 gene expression. 44 The study found that a locus of genetic variation on chromosome 19 that controls the expression of IFNL3 and IFNL4 is also associated with ACE2 expression, as was age. 44 These findings suggest the negative correlation between interferon response and ACE2 expression, which may influence viral entry and infection by viruses using the ACE2 receptor.

The role of the type II transmembrane protease TMPRSS2 and other host proteases involved in SARS Spike (S) protein cleavage and activation to promote efficient infection 45, 46 has not been studied in terms of host genetic heterogeneity. One highly cited SARS genetic risk assessment study 47 oligosaccharides. [47] [48] [49] [50] [51] [52] The function of this protein as a pathogen recognition receptor with direct involvement in SARS coronavirus infection makes its role as a host genetic restriction factor highly plausible. Chan et al 47 provided functional evidence for this hypothesis, demonstrating the differential impact of L-SIGN homozygosity for SARS-CoV adhesion, infection, proteasome-related viral degradation, and modulation of viral replication/titers. 47 The enthusiasm for these findings, however, was dampened by further studies that failed to replicate these results. 53 It was found that the median serum MBL in SARS patients was 0.733 μg/mL, which is significantly lower than the MBL level found in healthy control subjects (1.369 μg/mL, P-value = .0004). The impact of the MBL X/Y promoter polymorphisms and the structural A/B polymorphisms, as well as the three MBL haplotypes (YA, XA, and YB) on SARS susceptibility, was evaluated in this study. The haplotype YB, associated with MBL deficiency, was found to be more frequent in SARS patients (33.4%) compared to 24.7% frequency in the control group (P-value < .001, odds ratio/OR 1.52). 55 The study also elucidated some of the mechanisms underlying MBL effects, such as direct binding of MBL to SARS-CoV-1, complement activation, and MBL-mediated inhibition of viral infection. 55 control subjects. 56 This study reported a possible link between SARS severity and outcome and discovered a non-synonymous polymorphism affecting amino acid position 131 (arginine or histidine residue) of the Fc fragment of IgG receptor IIa (FCGR2A gene). The FcgammaRIIA-receptor R131 genotype was found to be significantly associated with SARS severity (P-value = .03), with a higher homozygosity frequency of this genotype among the ICU SARS patients compared to controls. 56 The encoded receptor is found on macrophages/neutrophils and other cells and is directly involved in innate/inflammatory response processes such as phagocytosis. 56 A study from Hong Kong included SARS patients (n = 495) and healthy controls (n = 578) who were genotyped for a panel of SNP markers, such as IFNγ, IL-10, TNFα, IL-12, RANTES, IL-10, Mig, and MCP-1 genes. 71 Polymorphisms in the IFNγ + 874A

and RANTES-28G alleles have been found to be significantly associated with SARS susceptibility and death in patients with SARS. 71 The IFNG + 874A allele was found more frequently in SARS patients (83.1%) compared to controls (66.3%, P-value < .001). This allele was significantly associated with SARS susceptibility (ie, subjects with IFNG + 874 AA or AT genotype had the OR of 5.19 and 2.57, respectively, of developing SARS [P-value < .001]). 71 In addition, subjects with the RANTES −28 GC and GG genotypes had the OR of 3.28 and 3.06, respectively, of developing SARS (P-value < .0001). 71 High circulating levels of the cytokine mac- In summary, the immunogenetics of coronavirus infections are largely understudied, and high-quality genetic association studies, genetic variant functional studies, and systems biology studies have not been performed, but they are needed in order to provide novel and important data regarding the genetic control of coronavirus infection, as well as host response and immunity. 

As ACE2 is the primary cellular receptor for SARS-CoV-2, studies have begun to investigate the relationship between ACE2 polymorphisms and COVID-19 severity. A recent study by Renieri and colleagues integrated whole-exome sequencing data with molecular dynamics simulations to identify and characterize 33 ACE2 variants from ~7000 Italian subjects. 103 teractions with the S glycoprotein. 104 A recent study of European and East Asian cohorts also identified two ACE2 variants (K26R and I468V) as having potentially lower binding affinities for the S protein. 105 Based on their proximity to important interacting regions on the S protein surface, the variants identified in these studies have the potential to alter the kinetics of viral binding and internalization and may explain the significant observed inter-individual variability in COVID-19 case severity.

A study by Pinto and colleagues analyzed 700 lung transcriptomic datasets from patients with diabetes, hypertension, and chronic obstructive pulmonary disease and found that global ACE2 expression was significantly higher than in the lungs of healthy patients. 106 This may explain why these individuals are predisposed to a higher severity of COVID-19; however, other studies suggest that higher ACE2 expression may be protective against lung injury, and ACE2 expression decreases with age (at least in an animal model). [107] [108] [109] Additional studies are required to determine if the modulation of ACE2 is a direct result of underlying comorbidities or if the increased/decreased expression of ACE2 in these individuals in certain anatomical locations/tissues is causal for severe COVID-19.

The increased severity of COVID-19 in males has also been speculatively associated with ACE2 polymorphisms and expression levels. Expression of ACE2 has generally been found to be higher in men than women, 110, 111 although some studies have reported equivocal expression levels. 112, 113 These conflicting data have led some studies to suggest that it is either the pattern or density of ACE2 expression in different anatomical locales rather than global differences in expression levels that influence sex-based differences in disease severity. [114] [115] [116] As ACE2 is encoded on the X chromosome, males only carry and express a single ACE2 variant on all cells, whereas females will likely express a mosaic pattern of ACE2 as determined by early X-inactivation events. 114 Thus, if men harbor an ACE2 variant that is more permissive for SARS-CoV-2 infection, all of their cells will express this risk variant.

The serine protease TMPRSS2 is the second host protein involved in SARS-CoV-2 infection and has received considerably less attention in genetic association studies to date. Russo et al identified an intergenic single nucleotide polymorphism (SNP) that was concomitantly associated with increased expression of TMPRSS2 and reduced expression of the interferon-inducible gene MX1 in lung tissue. 117 Individuals carrying this SNP may have an increased susceptibility to SARS-CoV-2 infection due to the increased expression of TMPRSS2 on the cell surface and the simultaneous dampening of the cellular antiviral response. A second study by Asselta and colleagues identified numerous SNPs in TMPRSS2 in an Italian cohort that were all predictively associated with higher gene expression levels. 112 Notably, one of these variants was associated with an androgen-responsive enhancer upstream of TMPRSS2, suggesting another possible mechanism for the enhanced severity of COVID-19 in males. While the preliminary identification of both ACE2 and TMPRSS2 variants potentially associated with COVID-19 susceptibility is promising, studies investigating the associations between these genetic variants and clinical outcomes in individuals infected with SARS-CoV-2 are lacking. Thus, classification of identified variants as protective or deleterious is premature until additional studies validating their biology can be undertaken. 

The critical role of exaggerated inflammatory responses leading to pathology associated with SARS-CoV-2, SARS-CoV-1, and MERS infections has been recently reviewed. 122 The release of proinflammatory cytokines (eg, IL-6, IL-1β, TNFα) in the course of infection, referred as "cytokine storm," is associated with the development of severe alveolar damage and lung inflammation/pathology characteristic of the acute respiratory distress syndrome. 123 122 It has been demonstrated that COVID-19 pneumonia is characterized by immune system dysregulation with excessive production of IL-6 and that elevated IL-6 levels were associated with and can predict respiratory failure and death in COVID-19 patients. 124, [126] [127] [128] In view of the role of IL-6 in COVID-19-associated pathology, different anti-IL-6 therapeutics have been considered for the treatment of severe COVID-19, including a monoclonal antibody/Sarilumab, which blocks the IL-6 receptor, that is currently in clinical trials. 122 The first studies suggesting the role of IL-6 polymorphisms in the progression of COVID-19 are underway. 129, 130 Using meta-analysis, a recent study analyzed 671 severe cases of bacterial and viral non-COVID-19 pneumonia and 2910 non-severe case of bacterial and viral pneumonia and found a significant association of the IL-6-174C allele (associated with a higher IL-6 level) with pneumonia severity (C allele vs G allele, OR: 1.33, 95% CI1.04-1.69, P-value = .019). 129 Given the importance of host genetic factors for infectious disease susceptibility and pathogenesis, the probable link between IL-6 genetic polymorphisms and COVID-19 warrants comprehensive investigation in large population based studies. per replication cycle, 135 which is significantly faster than the mutation rate for the human genome (10 −8 per generation). 136 This leads to the accrual of numerous quasi-species within a single infected individual, which may account for the observed differences in symptoms and disease severity. 137 Mutations among viral progeny may result in altered ACE2 binding interactions or shifted tissue tropism that promotes more or less aggressive and widespread infections.

Research is needed to investigate SARS-CoV-2 mutations within infected individuals to determine if there is a causal relationship between the emergence of specific mutations and disease severity or the spread of infection to specific tissues.

Certain mutations may provide a virus with distinct evolutionary advantages, such as changing a primary epitope to mediate escape from the host immune system or altering virulence factors to enhance transmission. These mutations may become established as a result of natural selection or vaccine selective pressure and subsequently give rise to new viral strains. 138 Forster et al reported the identification of three major variant types (A, B, C) of SARS-CoV-2 following phylogenetic analysis of 160 viral genomes. 139 Interestingly, the B-type viruses (T8782C + C28144T) were constrained to East Asia, while the A (T29095C) and C-type (T8782C + C28144T + G26144T) viruses were predominant in Europe and North America, which suggests that selective events have already occurred to allow the spread of SARS-CoV-2 variants beyond Asia. Real-time monitoring of global viral spread 140, 141 suggests that as many as eight strains of SARS-CoV-2 are currently circulating, although they continue to maintain a high degree of sequence similarity. This is consistent with observations from epidemiologic studies in Italy and the United States, suggesting that only 4-10 stable non-synonymous mutations have been introduced into the SARS-CoV-2 genome since its emergence in Wuhan several months ago. 142, 143 It is important to note that one such mutation in the S protein (D614G) appears to significantly increase the transmissibility of SARS-CoV-2, with strains harboring this mutation spreading rapidly throughout Europe and the United States since their origin. 144 It has been reported that individuals infected with the 614D variant have a higher case fatality rate that individuals infected with the 614G variant. 145 The authors suggest that differential S protein stability (and binding to ACE2) may play a role in the varying disease courses.

While the genome of SARS-CoV-2 appears to be relatively sta- countries. 149 While the S glycoprotein was largely conserved among these samples, a variant from India was identified with a mutation (R408I) in the receptor-binding domain (RBD) and was predicted to significantly alter ACE2 binding affinity. 149 A larger study by Ou et al identified 32 non-synonymous mutations in the S glycoprotein RBD across 1609 viral genomes and employed molecular dynamics simulations to characterize their binding with ACE2. 150 Three of these variants (V367F, W436R, and D364Y) were predicted to have binding affinities for ACE2 that were 100-fold higher than wildtype SARS-CoV-2, suggesting that these variants may be more infectious.

A single study from China has reported that patient-derived variants of SARS-CoV-2 harboring mutations in the S glycoprotein demonstrate markedly different infectivity in vitro. 151 The authors used ultra-deep sequencing to characterize 11 viral isolates from a hospital near Wuhan, China. They identified 33 unique mutations (6 in the S glycoprotein), with some variants demonstrating significantly greater cytopathology in Vero E6 cells relative to other viral isolates. While this certainly demonstrates the potential for mutations to drastically alter SARS-CoV-2 pathogenicity, we should point out that these results are derived from an in vitro assay employing a non-human cell line. Furthermore, the studies assessing the effects of S glycoprotein mutations on ACE2 binding affinity are currently limited to computational modeling. 149, 150 The development of biological assays employing human cell-based systems are greatly needed in order to validate the results of these early studies and reliably assess the pathogenic potential of SARS-CoV-2 variants.

A recent report of a SARS-CoV-2 genome-wide SNP association study using 152 full length viral genomes identified a SNP at nucleotide 11 083 associated with COVID-19 severity. This SNP is located in the non-structural nsp6 protein. 152 The authors also identified three host miRNAs (miR-485-3p, miR-539-3p, and miR-3149) that target this region of the genome when it contains the 11083G variant but not when it contains 11083T; they speculate that the G variant may sequester these miRNA species, which leads to alterations in the biological pathways (cell proliferation and autophagy) controlled by these miRNAs. Research efforts to gain a fundamental understanding of epigenetic mechanisms (eg, histone modifications, DNA methylation, and chromatin organization) in innate/cytokine immune response to SARS-CoV-2 infection and disease outcome are certainly needed and will help to inform the design of COVID-19 vaccine candidates. 154 We now understand how two host cell factors, ACE2 and TMPRSS2, are being used by SARS-CoV-2 virus for cell entry and spike protein priming. 40 We are learning more about the concomitant proinflammatory cytokine "storm" phenomenon, particularly in young patients, resulting from COVID-19. A recent modeling study exploring structural analysis of human ACE2 polymorphic variants and SARS-CoV-2 S protein complexes has identified two ACE2 polymorphisms (rs73635825 [S19P] and rs143936283 [E329G]) that may have a functional impact on susceptibility/resistance against SARS-CoV-2 infection. 155 In this regard, further work is required to determine specific host genetic variants in ACE2, TMPRSS2, CD147, MIF, cytokine, and other SARS-CoV-2-related host genes and their functional effects that correspond with differential severity to COVID-19 infection ( Figure 1) . Consequently, innate, humoral, and cellular genetic risk signatures of infection and/or clinical disease severity can be developed.

Replication studies will be critical to the evaluation of significant associations with specific variants in disease susceptibility genes.

The novel characteristics of SARS-CoV-2 and the general COVID-19 knowledge gap are impediments to the development of safe and effective vaccines against SARS-CoV-2, diagnostics/assays, antivirals, monoclonal antibodies, and outbreak control medical countermeasures that decrease diseases incidence and prevent mortality. 153 In particular, there is a critical need for both an im- To date, there are no systems biology studies that have examined the molecular risk signatures of SARS-CoV-2 infection and/or differential severity to COVID-19 infection, followed by a validation of the mechanism by which any identified signature functions. Highdimensional DNA (DNA-Seq) and RNA (RNA-Seq) sequencing may help discover mechanisms that control gene expression and gene/ geneset molecular signatures associated with SARS-CoV-2 infection and disease severity. State-of-the-art "omics" technologies, such as single-cell mRNA sequencing, mass cytometry, proteomics, metabolomics, epigenetics, multiplex cytokine/chemokine measurements, bioinformatics, and others, will need to be applied to identify specific susceptibility markers and precise correlates of protection for immunity with applications to SARS-CoV-2 virus or vaccine-induced immunity. Thus, current scientific efforts demonstrate a crucial need for COVID-19 host genetics studies.

A critical step toward fully comprehending disease pathogenesis, prevention, and treatment will be attaining a comprehensive understanding of SARS-CoV-2 and human host genetics. Although it is an enormous and ongoing task, it is critical to understand viral evolution over time and geography, genetic epidemiology, immune response to virus and vaccines, and how and why different populations experience different manifestations and severity of disease. Such studies must be geographically diverse and take into consideration change over time. 160 Indeed, acute lung injury was observed following viral challenge of vaccinated mice and nonhuman primates in trials of SARS-CoV-1 candidate vaccines, 161, 162 and pronounced hepatitis was observed among vaccinated ferrets, 163 suggesting that ADE may be a concern for vaccine development efforts against SARS-CoV-2. A Th2-biased cellular immune response following vaccination can also predispose individuals to enhanced disease upon viral infection. The production of Th2-associated cytokines (eg, IL-4, IL-5, IL-13) potentiates granulocyte infiltration, enhanced mucus production, and dampened cytotoxic T cell activity in the respiratory tract, ultimately leading to impaired respiratory function and a significant reduction in viral clearance. 164, 165 For these reasons, viral genetic sequencing studies over time and geography are critical.

Host genetic studies are much more expensive and complex.

Such studies run from candidate gene to GWAS and epigenetic studies. Current observations suggest that although infection rates seem to be similar, disease severity appears to be worse in males vs females, 10, [95] [96] [97] 166 that racial differences in disease severity may also occur, 100, 101, 167 and that differences in morbidity and mortality vary by age group. The basis for these differences remains unclear.

From a viral and host genetics point of view, there are critical knowledge gaps that direct our research agenda. Examples include the following:

• Understanding the role of ACE2, TMPRSS2, and other specific candidate host genes on COVID-19 infection, severity, and disease outcome.

• Performing candidate gene, epigenetic, and GWAS studies across different racial and ethnic populations in order to identify genes and haplotypes associated with differential factors of infection and clinical outcome, as well as vaccine response.

• Systems genetic and biology studies to understand differential and interacting genetic effects on disease severity and outcome through the lens of the immune response network theory. 168 • Studies of any differential effect of viral mutations and recombination events on differential disease severity in the context of host comorbidities and medication usage that blocks, suppresses, or activates differential host gene expression (eg, ACE2, TMPRSS2, etc).

• Understanding SAR-CoV-2 viral genetics over time and geography-particularly in terms of number and frequency of viral mutations and recombination events and their relationship to viral infectivity, transmissibility, disease severity, and clinical phenotype, viral burden, disease outcome, etc.

• Understanding potential interactions between SARS-CoV-2 and other respiratory co-infections (notably, between 20%-90% of COVID-19 patients in the United States were co-infected with at least one other respiratory pathogen).

• Understanding interactions and functional effects of various viral point mutations and recombination events on therapeutic monoclonal antibody, antiviral, and vaccine efficacy and possible adverse events.

We thank Caroline L. Vitse for her editorial assistance. This work was funded in parts by the National Institute of Allergy and Infectious Diseases grant numbers AI132348, AI121054, AI127365. 

Hosts and sources of endemic human coronaviruses

What's new with the old coronaviruses?

Prolonged shedding of human coronavirus in hematopoietic cell transplant recipients: risk factors and viral genome evolution

Host factors in coronavirus replication

Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences

Further evidence for bats as the evolutionary source of middle east respiratory syndrome coronavirus

Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV Immunological studies

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Novel Coronavirus Pneumonia Emergency Response Epidemiology T. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China

Severe outcomes among patients with coronavirus disease 2019 (COVID-19) -United States

Prominent changes in blood coagulation of patients with SARS-CoV-2 infection

COVID-19-related myocarditis in a 21-year-old female patient

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Neurotropism of SARS-CoV 2: mechanisms and manifestations

Olfactory and rhinological evaluations in SARS-CoV-2 patients complaining of olfactory loss

Neurological manifestations in COVID-19 caused by SARS-CoV-2

Evidence for Gastrointestinal Infection of SARS-CoV-2

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

HLA variation and disease

Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression

Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients

Genome wide identification of SARS-CoV susceptibility loci using the collaborative cross

The novel human coronaviruses NL63 and HKU1

The widening scope of coronaviruses

Identification of new respiratory viruses in the new millennium

Mouse susceptibility to mouse hepatitis virus infection is linked to viral receptor genotype

Role of mouse hepatitis virus (MHV) receptor murine CEACAM1 in the resistance of mice to MHV infection: studies of mice with chimeric mCEACAM1a and mCEACAM1b

Human aminopeptidase N is a receptor for human coronavirus 229E

Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor

Highly conserved regions within the spike proteins of human coronaviruses 229E and NL63 determine recognition of their respective cellular receptors

Genetic deficiency and polymorphisms of cyclophilin A reveal its essential role for Human Coronavirus 229E replication

Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A

Proteomics analysis unravels the functional repertoire of coronavirus nonstructural protein 3

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

ACE2 gene polymorphisms do not affect outcome of severe acute respiratory syndrome

Identification of an alternative 5'-untranslated exon and new polymorphisms of angiotensin-converting enzyme 2 gene: lack of association with SARS in the Vietnamese population

A gene locus that controls expression of ACE2 in virus infection

Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response

Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease

Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection

CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus

Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR

Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR

DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans

DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus

Lack of support for an association between CLEC4M homozygosity and protection against SARS coronavirus infection

Polymorphisms in the C-type lectin genes cluster in chromosome 19 and predisposition to severe acute respiratory syndrome coronavirus (SARS-CoV) infection

Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection

Influence of FcgammaRIIA and MBL polymorphisms on severe acute respiratory syndrome

Association between mannose-binding lectin gene polymorphisms and susceptibility to severe acute respiratory syndrome coronavirus infection

Mannose-binding lectin and upper respiratory tract infections in children and adolescents: a review

IL-12 RB1 genetic variants contribute to human susceptibility to severe acute respiratory syndrome infection among Chinese

DC-SIGN) -336A>G promoter polymorphism and severe acute respiratory syndrome in Hong Kong Chinese

Association of ICAM3 genetic variant with severe acute respiratory syndrome

The interferon gamma gene polymorphism +874 A/T is associated with severe acute respiratory syndrome

The association of RANTES polymorphism with severe acute respiratory syndrome in Hong Kong and Beijing Chinese

Functional polymorphisms of the CCL2 and MBL genes cumulatively increase susceptibility to severe acute respiratory syndrome coronavirus infection

Mannose-binding lectin deficiency and respiratory tract infection

Pathogenesis of severe acute respiratory syndrome

Low serum mannose-binding lectin level increases the risk of death due to pneumococcal infection

MBL genotype and risk of invasive pneumococcal disease: a case-control study

A meta-analysis of MBL2 polymorphisms and tuberculosis risk

Age-dependent association of human mannose-binding lectin mutations with susceptibility to invasive meningococcal disease in childhood

Association of cytokine and chemokine gene polymorphisms with severe acute respiratory syndrome

Macrophage migration inhibitory factor enhances influenza-associated mortality in mice

The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia

Functional polymorphisms of macrophage migration inhibitory factor as predictors of morbidity and mortality of pneumococcal meningitis

Association of HLA class I with severe acute respiratory syndrome coronavirus infection

Association of human-leukocyte-antigen class I (B*0703) and class II (DRB1*0301) genotypes with susceptibility and resistance to the development of severe acute respiratory syndrome

Epidemiological and genetic correlates of severe acute respiratory syndrome coronavirus infection in the hospital with the highest nosocomial infection rate in Taiwan in 2003

Human leukocyte antigen susceptibility map for SARS-CoV-2

Immunogenetics in SARS: a case-control study

Association of human leukocyte antigen class II alleles with severe acute respiratory syndrome in the Vietnamese population

Human-leukocyte antigen class I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection

Molecular immune pathogenesis and diagnosis of COVID-19

Influence of HLA gene polymorphisms on susceptibility and outcome post infection with the SARS-CoV virus

Lack of association between HLA-A, -B and -DRB1 alleles and the development of SARS: a cohort of 95 SARS-recovered individuals in a population of Guangdong, southern China

Host determinants of MERS-CoV transmission and pathogenesis

Species-specific colocalization of middle east respiratory syndrome coronavirus attachment and entry receptors

Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4

Association of human leukocyte antigen class II alleles with severe Middle East respiratory syndrome-coronavirus infection

Cytokine SNPs: Comparison of allele frequencies by race and implications for future studies

High-resolution HLA alleles and haplotypes in the United States population

HLA DNA sequence variation among human populations: molecular signatures of demographic and selective events

Meta-analysis of age-related gene expression profiles identifies common signatures of aging

Sex-biased gene expression

The evolution of sex-biased genes and sex-biased gene expression

Clinical characteristics of coronavirus disease 2019 in China

Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection

Spread of SARS-CoV-2 in the icelandic population

Relationship between the ABO blood group and the COVID-19 susceptibility

Testing the association between blood type and COVID-19 infection, intubation, and death. medRxiv

Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 -COVID-NET, 14 States

Characteristics and clinical outcomes of adult patients hospitalized with COVID-19 -Georgia

A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex

ACE2 variants underlie interindividual variability and susceptibility to COVID-19 in Italian population

Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility

Genetic variability of human angiotensin-converting enzyme 2 (hACE2) among various ethnic populations

ACE2 expression is increased in the lungs of patients with comorbidities associated with severe COVID-19. medRxiv

Will children reveal their secret? The coronavirus dilemma

Age-and gender-related difference of ACE2 expression in rat lung

Lessons from SARS: control of acute lung failure by the SARS receptor ACE2

Landscape of X chromosome inactivation across human tissues

Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan

ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy

Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ACE2, the receptor of 2019-nCov. medRxiv

ACE 2 coding variants: a potential X-linked risk factor for COVID-19 disease

Higher mortality in men from COVID19 infection-understanding the factors that drive the differences between the biological sexes

Impact of sex and gender on COVID-19 outcomes in Europe

Genetic analysis of the novel SARS-CoV-2 host receptor TMPRSS2 in different populations

HLA predictions from the bronchoalveolar lavage fluid samples of five patients at the early stage of the Wuhan seafood market COVID-19 outbreak

In silico identification of vaccine targets for 2019-nCoV

Prediction of SARS-CoV-2 epitopes across 9360 HLA class I alleles

The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis. medRxiv

IL-6: relevance for immunopathology of SARS-CoV-2

COVID-19: an immunopathological view. mSphere

Clinical and immunologic features in severe and moderate coronavirus disease 2019

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19

Interleukin-6 as a potential biomarker of COVID-19 progression

Anti-IL-6 Receptor Antibody Treatment for Severe COVID-19 and the Potential Implication of IL-6 Gene Polymorphisms in Novel Coronavirus Pneumonia

Interleukin 6 polymorphisms as an indicator of COVID-19 severity in humans

The COVID-19 host genetics initiative

The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic

National Institute for Health Research. Genetics of susceptibility and mortality in critical care (GenOMICC)

Mechanisms of viral mutation

Estimating the human mutation rate from autozygous segments reveals population differences in human mutational processes

SARS-CoV-2 exhibits intra-host genomic plasticity and low-frequency polymorphic quasispecies

Natural selection and infectious disease in human populations

Phylogenetic network analysis of SARS-CoV-2 genomes

The Nextstrain Team. Genomic epidemiology of novel coronavirus-Global sampling

Nextstrain: real-time tracking of pathogen evolution

Relatively Stable SARS-CoV-2 Genome Is Good News for a Vaccine

Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv

SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate

Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant

Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio

The mechanism of resistance to favipiravir in influenza

Analysis of the mutation dynamics of SARS-CoV-2 reveals the spread history and emergence of RBD mutant with lower ACE2 binding affinity

Emergence of RBD mutations in circulating SARS-CoV-2 strains enhancing the structural stability and human ACE2 receptor affinity of the spike protein

Patient-derived mutations impact pathogenicity of SARS-CoV-2. medRxiv

SARS-CoV-2 genetic variations associated with COVID-19 severity

NIAID strategic plan for COVID-19 research

Epigenetic landscape during coronavirus infection

Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein

The COVID-19 vaccine development landscape

Developing Covid-19 vaccines at pandemic speed

Characteristics of and Important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the chinese center for disease control and prevention

Tortoises, hares, and vaccines: a cautionary note for SARS-CoV-2 vaccine development

Medical countermeasures analysis of 2019-nCoV and vaccine risks for antibody-dependent enhancement (ADE) (2/27/2020)

Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets

Rapid COVID-19 vaccine development

Immunological lessons from respiratory syncytial virus vaccine development

Gender differences in patients with COVID-19: Focus on severity and mortality

Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19?

Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century

The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity